The FDA has approved Nucala (mepolizumab; GlaxoSmithKline) for injection as add-on maintenance treatment of patients with severe asthma aged ≥12 years.
Dermatologist, allergist, primary care doctors failed to identify etiology of rash over several months
The American Academy of Dermatology has issued new recommendations regarding potentially unnecessary dermatologic tests and treatments as part of the Choosing Wisely campaign.
A study in the American Journal of Respiratory and Critical Care Medicine reports that older asthma patients, particularly those treated with inhaled corticosteroids, appear to be at an increased risk for treatment failure compared to those under the age of 30.
A new study suggests that many patients with COPD may be undertreated (particularly with long-acting maintenance medications), despite recommended treatment guidelines.
Currently, COPD guidelines recommend that patients with acute exacerbations be treated with systemic corticosteroids for 7-14 days, however, an updated review suggests that corticosteroid treatment of a shorter duration may be as effective as conventional longer-duration therapy.
A panel of expert advisors to the U.S. Food and Drug Administration voted overwhelmingly against moving the allergy drug Singulair from prescription to over-the-counter status.
Drugs in the Pipeline
GlaxoSmithKline announced that the primary endpoint for its Phase 3 study of mepolizumab was met for the reduction in the frequency of exacerbations, in patients with severe eosinophilic asthma.
Pediatric allergic contact dermatitis (ACD) to methylisothiazolinone (MI) may be increasing and should be considered in cases with a history of wet wipe use.
The Global Initiative for Asthma (GINA)'s 2012 Guidelines provides a stepwise plan for treatment of asthma, based on disease severity.